| Primary |
| Factor Viii Deficiency |
46.3% |
| Haemophilia |
11.9% |
| Drug Use For Unknown Indication |
7.5% |
| Haemorrhage |
7.5% |
| Haematoma |
4.5% |
| Haematuria |
4.5% |
| Joint Sprain |
4.5% |
| Von Willebrand's Disease |
4.5% |
| Factor Viii Inhibition |
3.0% |
| Activated Partial Thromboplastin Time Prolonged |
1.5% |
| Anticoagulant Therapy |
1.5% |
| Splenic Rupture |
1.5% |
| Surgery |
1.5% |
|
| Factor Viii Inhibition |
38.3% |
| Hepatitis C |
14.9% |
| Death |
8.5% |
| Haemorrhage |
4.3% |
| Von Willebrand's Disease |
4.3% |
| Anaemia |
2.1% |
| Haemoptysis |
2.1% |
| Hepatitis C Virus |
2.1% |
| Hiv Test Positive |
2.1% |
| Impaired Healing |
2.1% |
| Liver Injury |
2.1% |
| Maternal Exposure During Pregnancy |
2.1% |
| Muscle Haemorrhage |
2.1% |
| Peripheral Vascular Disorder |
2.1% |
| Rash |
2.1% |
| Renal Impairment |
2.1% |
| Synovitis |
2.1% |
| Thrombosis |
2.1% |
| White Blood Cell Count Increased |
2.1% |
|
| Secondary |
| Factor Viii Deficiency |
52.3% |
| Haematuria |
8.5% |
| Haemorrhage |
8.3% |
| Haematoma |
7.8% |
| Joint Sprain |
7.8% |
| Haemophilia |
7.0% |
| Pulmonary Haemorrhage |
2.1% |
| Subdural Haematoma |
1.0% |
| Hepatitis C |
0.8% |
| Benign Prostatic Hyperplasia |
0.5% |
| Coagulation Factor Viii Level |
0.5% |
| Immune Tolerance Induction |
0.5% |
| Knee Operation |
0.5% |
| Product Used For Unknown Indication |
0.5% |
| Pulmonary Embolism |
0.5% |
| Anaemia |
0.3% |
| Depression |
0.3% |
| Factor Viii Inhibition |
0.3% |
| Influenza |
0.3% |
| Insomnia |
0.3% |
|
| Hepatitis C |
35.0% |
| Factor Viii Inhibition |
19.4% |
| Hiv Infection |
16.5% |
| White Blood Cell Count Increased |
9.7% |
| Haemoptysis |
1.9% |
| Muscle Haemorrhage |
1.9% |
| Pulmonary Haemorrhage |
1.9% |
| Subdural Haematoma |
1.9% |
| Tropical Spastic Paresis |
1.9% |
| Von Willebrand's Disease |
1.9% |
| Drug Ineffective |
1.0% |
| Hepatic Neoplasm Malignant |
1.0% |
| Hepatitis A |
1.0% |
| Jaundice |
1.0% |
| Pharmaceutical Product Complaint |
1.0% |
| Pneumonia |
1.0% |
| Transmission Of An Infectious Agent Via A Medicinal Product |
1.0% |
| Vomiting |
1.0% |
|
| Concomitant |
| Hiv Infection |
63.7% |
| Drug Use For Unknown Indication |
11.2% |
| Factor Viii Deficiency |
7.9% |
| Acute Myeloid Leukaemia |
2.6% |
| Hepatitis C |
2.4% |
| Haemophilia |
2.0% |
| Gastric Ulcer |
1.3% |
| Immunosuppression |
1.3% |
| Antibiotic Prophylaxis |
0.9% |
| Coagulation Factor |
0.9% |
| Haemorrhage |
0.9% |
| Gastritis |
0.7% |
| Gastrointestinal Disorder |
0.7% |
| Hyperuricaemia |
0.7% |
| Insomnia |
0.7% |
| Prophylaxis |
0.7% |
| Acquired Haemophilia |
0.4% |
| Dehydration |
0.4% |
| Heart Transplant |
0.4% |
| Hepatitis |
0.4% |
|
| Hepatitis C |
13.3% |
| Death |
8.9% |
| Hepatic Cirrhosis |
8.9% |
| Hyperglycaemia |
8.9% |
| Tumour Lysis Syndrome |
8.9% |
| Pulmonary Hypertension |
6.7% |
| Viral Load Increased |
6.7% |
| Muscle Haemorrhage |
4.4% |
| Renal Failure |
4.4% |
| Sepsis |
4.4% |
| White Blood Cell Count Decreased |
4.4% |
| Anastomotic Haemorrhage |
2.2% |
| Cerebral Haematoma |
2.2% |
| Cerebral Haemorrhage |
2.2% |
| Diarrhoea |
2.2% |
| Dizziness |
2.2% |
| Epididymitis |
2.2% |
| Factor Viii Inhibition |
2.2% |
| Haematochezia |
2.2% |
| Haematoma |
2.2% |
|
